$148 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 35 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | DISC MEDICINE INC | $6,193,800 | – | 139,500 | +100.0% | 4.20% | – | |
PRAX | New | PRAXIS PRECISION MEDICINES I | $4,887,500 | – | 4,250,000 | +100.0% | 3.31% | – |
CLNN | New | CLENE INC | $3,731,520 | – | 4,240,846 | +100.0% | 2.53% | – |
IKNA | New | IKENA ONCOLOGY INC | $3,660,480 | – | 558,000 | +100.0% | 2.48% | – |
IMVT | New | IMMUNOVANT INC | $2,689,092 | – | 141,755 | +100.0% | 1.82% | – |
New | VERASTEM INC | $2,232,000 | – | 300,000 | +100.0% | 1.51% | – | |
New | ROIVANT SCIENCES LTDshares | $2,217,600 | – | 220,000 | +100.0% | 1.50% | – | |
MORF | New | MORPHIC HOLDING INC | $1,003,275 | – | 17,500 | +100.0% | 0.68% | – |
ARWR | New | ARROWHEAD PHARMACEUTICALS INC | $980,650 | – | 27,500 | +100.0% | 0.66% | – |
OLMA | New | OLEMA PHARMACEUTICALS INC | $955,500 | – | 105,814 | +100.0% | 0.65% | – |
BMEA | New | BIOMEA FUSION INC | $878,000 | – | 40,000 | +100.0% | 0.60% | – |
DYN | New | DYNE THERAPEUTICS INC | $821,250 | – | 73,000 | +100.0% | 0.56% | – |
KRON | New | KRONOS BIO INC | $541,800 | – | 315,000 | +100.0% | 0.37% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
KURA ONCOLOGY INC. COMMON STOCK | 20 | Q2 2024 | 8.1% |
IRIDEX CORP | 20 | Q3 2019 | 8.1% |
ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
VERACYTE INC | 19 | Q3 2019 | 10.1% |
APELLIS PHARMACEUTICALS INC | 18 | Q4 2023 | 18.4% |
ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-30 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.